Hyperphosphatemia is a strong predictor of overall
|
|
- Cameron Webster
- 6 years ago
- Views:
Transcription
1 Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics Sunil V. Badve,* Deborah L. Zimmerman,* Greg A. Knoll, * Kevin D. Burns,* and Brendan B. McCormick* *Division of Nephrology, Department of Medicine, University of Ottawa and The Ottawa Hospital Ottawa, Canada, Kidney Research Centre and The Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Canada Background and objectives: Hyperphosphatemia is an independent risk factor for mortality in ESRD, but factors regulating phosphate clearance on peritoneal dialysis (PD) are incompletely understood. The objective of this study was to test the hypothesis that peritoneal phosphate clearance is better with continuous ambulatory PD (CAPD) as compared with continuous cyclic PD (CCPD) after adjusting for membrane transport status. Design, setting, participants, & measurements: In this cross-sectional and retrospective study, measurements of peritoneal phosphate clearance of 129 prevalent PD patients were reviewed. Patients were divided according to membrane transport status (high, high average, low average-low categories) and PD modality (CAPD or CCPD). Results: Among high transporters, peritoneal phosphate clearances were comparable in both modalities. However, treatment with CAPD was associated with increased peritoneal phosphate clearance compared with CCPD among high-average transporters ( versus L/wk/1.73 m 2, P 0.01), and low-average-low transporters ( versus L/wk/1.73 m 2, P 0.034). On multivariate linear regression, PD modality, membrane transport category, and peritoneal creatinine clearance, but not Kt/V urea, were independently associated with peritoneal phosphate clearance. Conclusions: Peritoneal phosphate clearance is determined by PD modality and membrane transport category, suggesting that PD regimes with longer dwell times may help control hyperphosphatemia in lower transporters. Clin J Am Soc Nephrol 3: , doi: /CJN Received January 10, Accepted July 10, Published online ahead of print. Publication date available at Correspondence: Dr. Brendan B. McCormick, Division of Nephrology, 1967 Riverside Drive, Ottawa, Ontario, Canada, K1H 7W9. Phone: , ext ; Fax: ; bmccormick@ottawahospital.on.ca Hyperphosphatemia is a strong predictor of overall and cardiovascular mortality in ESRD patients treated with peritoneal dialysis (PD) therapy (1,2). Despite this well established risk, approximately 40% of PD patients have serum phosphate concentrations above levels recommended by current guidelines (2). Control of hyperphosphatemia is difficult to achieve for several reasons. First, dietary phosphate restriction is characterized by poor adherence and if achieved can result in protein malnutrition (3). Second, the use of phosphate binders, although effective, is associated with secondary effects, including hypercalcemia, gastrointestinal disturbances, and poor adherence (4,5). Finally, in PD patients phosphate control is known to deteriorate as residual renal function declines, which may contribute to sustained hyperphosphatemia (6). In addition to these factors, peritoneal phosphate clearance plays a role in achieving adequate phosphate homeostasis, although this component of phosphate balance has not been well studied. In PD patients, diffusive and convective transport of phosphate across the peritoneal membrane contributes to overall phosphate homeostasis. Phosphate is surrounded by an aqueous layer because of its hydrophilic properties and may behave like a larger molecule with respect to solute clearance (7). Because peritoneal phosphate clearance is time-dependent, it may be altered with different peritoneal dialysis modalities and across different peritoneal membrane transport categories (8). These clearance properties have not been well characterized because previous studies were limited by small sample size and no adjustment for peritoneal membrane transport category (9 11). Accordingly, the objective of this study was to determine the effect of membrane transport characteristics and PD modality on peritoneal phosphate clearance in a prevalent PD population. We hypothesized that peritoneal phosphate clearance would be inferior in patients with lower transport membranes when treated with PD modalities with shorter dwell times such as continuous cyclic PD (CCPD) compared with those treated with continuous ambulatory PD (CAPD). Materials and Methods Study Population This was a cross-sectional and retrospective study conducted at The Ottawa Hospital home dialysis unit. The Ottawa Hospital is a tertiary care center providing regional dialysis services to a population of 1.5 million. The study protocol was approved by The Ottawa Hospital Research Ethics Board. Patients included in this study were on CAPD Copyright 2008 by the American Society of Nephrology ISSN: /
2 1712 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 or CCPD for a minimum of 3 mo and were followed between January 1, 2005 and December 31, We excluded patients who were treated with nocturnal intermittent PD. Data Collection Baseline patient demographic characteristics were collected and peritoneal membrane transport category was determined by the closest peritoneal equilibration test (PET) to the time of measurement of dialysis adequacy. PET tests were performed in the morning with 2L of 2.5% dextrose solution (Dianeal 2.5%, Baxter Healthcare, Deerfield, Illinois, USA). The long overnight dwell before the PET was performed with 2.5% Dianeal solution. Dialysate/plasma (D/P) creatinine ratio was measured at 4 h and used to classify patients as low (D/P creatinine 0.49), low average (D/P creatinine 0.50 to 0.64), high average (D/P creatinine 0.65 to 0.80) or high (D/P creatinine 0.81) transporters according to the criteria defined by Twardowski et al. (12). CAPD was defined as three or more manual twin bag exchanges per day and CCPD was defined as three or more exchanges using a cycler with at least one daytime dwell. There was no restriction on maximum number of exchanges or volumes. Cycler patients with more than one daytime exchange were classified as CCPD. In our program, all PD patients undergo measurements of dialysis adequacy and phosphate clearance 4 wk after initiation, and then every 6 mo. Additional adequacy testing is performed 1 mo after any change in the dialysis prescription or when indicated clinically. If patients had more than one measurement of dialysis adequacy and phosphate clearance, the first one was included in the analysis. Measurements of both peritoneal and renal Kt/V urea and creatinine clearances, GFR, body surface area (BSA), and protein catabolic rate were calculated by using PD Adequest 2.0 for Windows software (Baxter Healthcare, Deerfield, Illinois, USA). Presence of residual renal function was defined as GFR 1 ml/min/1.73 m 2. Phosphate concentration in serum and urine were measured using Ortho Vitros 250 Analyser (Ortho-Clinical Diagnostics Inc., Raritan, New Jersey), dialysate phosphate concentration was measured using a Beckman Coulter LX20 (Beckman Coulter Inc., Mississauga, Canada). Coefficient of variation was between 1 and 2% for all phosphate measurements. Phosphate clearances were calculated as follows: (13) Peritoneal phosphate clearance (L/wk/1.73 m 2 ) (dialysate phosphate in mmol/l plasma phosphate in mmol/l) 24 h effluent dialysate volume (L) 7 (corrected for 1.73 m 2 BSA). Renal phosphate clearance (L/wk/1.73 m 2 ) (urine phosphate in mmol/d plasma phosphate in mmol/l) 7 (corrected for 1.73 m 2 BSA). Statistical Analyses Results were expressed as frequencies and percentages for categorical variables, mean SD for continuous variables, and median and interquartile range for nonparametric data. Patients were divided according to PD modality (CAPD or CCPD) as well as by peritoneal membrane transport status. Low and low-average transporters were combined because of the small number of low transporters in our population. Differences between the two PD modalities were compared using the t test where data were parametric and the Mann-Whitney U test if nonparametric. Distributions of categorical variables across the three transport groups were compared by means of 2 test, continuous variables by one-way ANOVA if data were parametric, and Kruskal- Wallis test if nonparametric. Correlation between two continuous variables was expressed as Pearson s correlation coefficient. Simple linear regression was used to analyze the determinants of peritoneal phosphate clearance. Categorical variables entered in the regression included gender, diabetes, PD modality, and peritoneal membrane transport status. The following continuous variables were used in the model: age, time spent on PD, body mass index, protein catabolic rate, serum albumin, GFR, serum phosphate, dialysis volume, ultrafiltration volume, peritoneal creatinine clearance, and peritoneal Kt/V. P values 0.05 were considered statistically significant. Statistical analyses were performed using Stata/SE 9.2 (College Station, TX, USA) statistical software. Results Patient Characteristics During the 2-yr study period, a total of 194 PD patients underwent at least one measurement of dialysis adequacy. Of these 194 patients, 27 patients were excluded because they had not completed 3 mo on PD, 24 automated PD (APD) patients were excluded because of treatment with nocturnal intermittent PD, 4 were excluded for incomplete data collection, and 10 were excluded because of incremental PD with fewer than three exchanges per day. The remaining 129 patients were included in this analysis. Characteristics of the population by modality and membrane transport category are described in Tables 1a and 1b respectively. Of the 129 patients, 62 (48%) patients were treated with CAPD, and 67 (52%) with CCPD. When classified by membrane transport category, 22 (17%) were high transporters, 76 (59%) were high-average transporters, and 31 (24%) were low-average or low transporters. Patients treated with CCPD were more likely to be male, and tended to have lower residual GFR and higher transporting membranes. When classified according to the membrane transport category, the only significant baseline difference was the higher serum albumin in lower transporters. Peritoneal Ultrafiltration and Urea and Creatinine Clearances There were no significant differences in peritoneal ultrafiltration between the two PD modalities or across the membrane transport categories (Tables 2a, 2b). The CCPD group had higher peritoneal Kt/V urea than the CAPD group ( versus P 0.001), but there was no difference in peritoneal creatinine clearance between the two modalities ( versus L/wk/1.73 m 2 BSA, P 0.11) (Table 2a). Patients with high-transport membranes had higher peritoneal Kt/V ( versus versus , for high, high-average, and low-average-low membranes respectively, P 0.035) and higher peritoneal creatinine clearance ( versus versus L/wk/1.73 m 2, for high, high-average, and low-average-low membranes respectively, P 0.001) (Table 2b). Peritoneal Phosphate Clearance When examined by PD modality alone, there was no significant difference in peritoneal phosphate clearance between those treated with CCPD or CAPD ( versus L/wk/1.73 m 2, P 0.199). When examined by membrane transport category alone, the patients in the low-average and low membrane transport categories had lower peritoneal phosphate clearance than the high-
3 Clin J Am Soc Nephrol 3: , 2008 Peritoneal Phosphate Clearance 1713 Table 1a. Patient characteristics, comparison across peritoneal dialysis (PD) modality Variable Total CAPD CCPD P Value N (48.1%) 67 (51.9%) Male gender 70 (54.3%) 26 (41.9%) 44 (65.7%) Age (years) Diabetes 40 (31%) 20 (32.3%) 20 (29.9%) Time spent on PD (months) a 9.1 ( ) 8.4 ( ) 10.1 ( ) BMI (kg/m 2 ) RRF present 89 (68.9%) 52 (83.9%) 37 (55.2%) GFR (ml/min) a 2.6 ( ) 3.9 ( ) 1.3 (0-3.6) Urine output (L/day) a 0.49 ( ) 0.69 ( ) 0.26 (0-0.65) D/P creatinine Membrane status High 22 (17.1%) 6 (9.7%) 16 (23.9%) High-average 76 (58.9%) 36 (58.1%) 40 (59.7%) Low-average & low 31 (24%) 20 (32.3%) 11 (16.4%) PCR (g/kg/day) Serum urea (mmol/l) Plasma creatinine ( mol/l) Serum albumin (g/l) Serum phosphate (mmol/l) a Median (interquartile range). CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis; NIPD, nocturnal intermittent peritoneal dialysis; BMI, body mass index; RRF, residual renal function; D/P creatinine, dialysate plasma creatinine ratio at 4 h; PCR, protein catabolic rate. Table 1b. Patient characteristics, comparison across peritoneal membrane transport status Variable High High-Average Low-Average and Low P Value N 22 (17.1%) 76 (58.9%) 31 (24%) Male gender 16 (72.7%) 41 (53.9%) 13 (41.9%) Age (years) Diabetes 5 (22.7%) 26 (34.2%) 9 (29%) Time spent on PD (months) a 7.8 ( ) 9.4 (6.5-22) 10.4 ( ) BMI (kg/m 2 ) RRF present 14 (63.6%) 55 (72.4%) 20 (64.5%) GFR (ml/min) a 2.1 (0-4.3) 2.6 ( ) 3.2 ( ) Urine output (L/day) a 0.41 (0-0.66) 0.51 ( ) 0.5 ( ) D/P creatinine PD modality CAPD 6 (27.3%) 36 (47.4%) 20 (64.5%) CCPD 16 (72.7%) 40 (52.6%) 11 (35.5%) PCR (g/kg/day) Urea (mmol/l) Creatinine ( mol/l) Albumin (g/l) Phosphate (mmol/l) a Median (interquartile range). average or the high membrane transport categories ( versus versus L/wk/1.73 m 2, respectively, P 0.001). When peritoneal phosphate clearance by modality was examined for each membrane category, there was no significant difference in phosphate clearance between the modalities in the high transport category (Figure 1 and Table 3). In the high average category, however, there was significantly higher
4 1714 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 Table 2a. Fluid and solute clearances, comparison across PD modality Variable Total CAPD CCPD P Value Dialysate volume (L/day) Ultrafiltration on PD (L/day) a 1.04 ( ) 1.16 ( ) 0.99 ( ) Peritoneal Kt/V Peritoneal creatinine clearance (L/wk/1.73 m 2 BSA) Peritoneal P/phosphate clearance (L/wk/1.73 m 2 BSA) a Median (interquartile range). P value by ANOVA if parametric variable, and by Kruskal-Wallis test if nonparametric. BSA, body surface area. Table 2b. Fluid and solute clearances, comparison across peritoneal membrane transport status Variable High High-Average Low-Average and Low P Value Dialysate volume (L/day) Ultrafiltration on PD (L/day) a 1.07 ( ) 1.03 ( ) 1.23 ( ) Peritoneal Kt/V Peritoneal creatinine clearance (L/wk/1.73 m 2 BSA) Peritoneal phosphate clearance (L/wk/1.73 m 2 BSA) a Median (interquartile range). P value by ANOVA if parametric variable, and by Kruskal-Wallis test if nonparametric. Figure 1. Mean peritoneal phosphate clearance (L/wk/1.73 m 2 BSA) according to peritoneal membrane transport category and peritoneal dialysis modality. CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis; H, high transport category; HA, high-average transport category, LA & L: combined low-average and low transport category. phosphate clearance among those treated with CAPD compared with CCPD ( versus L/wk/1.73 m 2, P 0.01). In the low-average and low membrane category, treatment with CAPD was associated with significantly higher phosphate clearance than CCPD ( versus L/wk/1.73 m 2, P 0.034). There was no significant difference in peritoneal creatinine clearance between the two modalities across any of the membrane transport categories (Table 3). Determinants of Peritoneal Phosphate Clearance There was a strong correlation between mean peritoneal phosphate clearance and mean peritoneal creatinine clearance (r 0.67, P 0.001). On simple linear regression, peritoneal creatinine clearance and Kt/V directly correlated with peritoneal phosphate clearance whereas serum albumin, high-average transporter category, and low-average -low transporter category were negatively correlated with peritoneal phosphate clearance (Table 4). Multivariate linear regression confirmed that both membrane transport category and PD modality were independently associated with peritoneal phosphate clearance. It is important to note that these findings were independent of peritoneal creatinine clearance. With CAPD as the reference, multivariate regression showed that CCPD had inferior peritoneal phosphate clearance. With high transport status as the reference, high-average and low-average-low transporters both had inferior peritoneal phosphate clearance. Peritoneal creatinine clearance was positively associated with peritoneal phosphate clearance but peritoneal Kt/V urea did not remain significant on multivariate regression analysis. Discussion The major novel finding in this study is that PD modality is a significant determinant of peritoneal phosphate clearance with superior peritoneal phosphate clearance associated with treatment with CAPD except among high transporters. This clinical study is the first to address the determinants of peritoneal phosphate clearance in a large, prevalent PD population with standard dialysis prescriptions. These findings are important considering the fact that in the Unites States about twothirds and globally about one-third of PD patients are treated with automated peritoneal dialysis (APD) (14 15). Patient pref-
5 Clin J Am Soc Nephrol 3: , 2008 Peritoneal Phosphate Clearance 1715 Table 3. Peritoneal creatinine and phosphate clearances according to peritoneal membrane transport characteristic and PD modality Peritoneal Membrane Transport CAPD CCPD P Value Peritoneal creatinine clearance High High-average Low-average and low Peritoneal phosphate clearance High High average Low-average and low Table 4. Determinants of peritoneal phosphate clearance, by linear regression Variable Standardized Beta Univariate Analysis Regression Coefficient P value Standardized Beta Multivariate Analysis Regression Coefficient P value Age Female gender Diabetes Time on PD BMI PCR Serum albumin GFR Peritoneal membrane transport status High Reference Reference High-average Low-average and low Dialysate volume PD modality CAPD Reference Reference CCPD Ultrafiltration on PD Peritoneal creatinine clearance Peritoneal Kt/V erence and lifestyle are the most common indications to choose APD as a PD modality (16), and many low average and low transporters are treated with APD and achieve adequate Kt/V urea and ultrafiltration with this modality. Our data suggest that peritoneal phosphate clearance should also be considered when choosing PD modality. Modality choice may be of particular significance to anuric PD patients because these patients are known to have worse phosphate control than those with residual GFR (6). For an anuric patient with a constant daily phosphate load and no net flux of phosphate from bone, the serum phosphate is an inverse function of the peritoneal phosphate clearance. Thus, our finding that treatment with CAPD was associated with an increase in peritoneal phosphate clearance of 16% among high-average transporters and 23% among low-average and low transporters compared with CCPD suggests that PD modality may play an important role in control of serum phosphate among anuric patients. Among anuric patients, this difference in phosphate clearance between the two modalities could result in differences in serum phosphate of 0.2 to 0.4 mmol/l, depending on baseline levels. In patients with well preserved residual renal function these differences in peritoneal clearances are unlikely to be of clinical significance because they are minor in comparison to renal phosphate clearance (6). We observed a strong correlation between peritoneal phosphate and creatinine clearance in both of the PD modalities. In our multivariate regression analysis, peritoneal phosphate clearance was independently associated with peritoneal creatinine clearance and not with Kt/V urea. These findings confirm that peritoneal creatinine clearance can be used as a surrogate
6 1716 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 3: , 2008 marker for peritoneal phosphate clearance and highlight the peril of relying solely on Kt/V urea as a measure of PD adequacy. The recently published International Society for Peritoneal Dialysis guidelines on PD adequacy recommend a separate target of at least 45 L/wk/1.73 m 2 of creatinine clearance, but the 2006 National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines on PD adequacy recommend only a target for Kt/V (17,18). Our data suggest that focusing only on urea for assessment of dialysis adequacy may result in inadequate clearance of phosphate (19). It is known that experimentally, peritoneal urea and creatinine clearances can be maximized on APD through manipulation of the number of cycles, total cycler volume, and the amount of tidal volume (20,21). Juergensen and colleagues have reported that increasing the number of APD cycles from 7 to 12 and the total cycler volume by 70% to 24 L improved peritoneal phosphate clearance by 19% (20). The effect of decreasing the number of cycles and increasing dwell time on peritoneal phosphate clearance on APD has not been systematically studied. Our findings of increased peritoneal phosphate clearance among lower transporters with CAPD suggest that a strategy of increasing cycler dwell times may be effective in the patients with lower membrane transport status. For those with high transporting membranes more frequent cycling as described by Jurgensen et al. may be an effective strategy. This highlights the importance of individualizing PD prescriptions on the basis of membrane transport status. Our findings expand upon the work of other groups who have compared phosphate clearance between CAPD and CCPD by adjusting for peritoneal membrane transport category. Sedlacek et al. reported that phosphate clearance is increased in higher transporters compared with lower transporters in CAPD as well as CCPD groups (9). Prior direct comparisons of phosphate clearance between CAPD and CCPD, however, have not shown significant differences in peritoneal phosphate clearance (9,10), or shown worse peritoneal phosphate clearance on CAPD (11). The lack of separate analysis of membrane and modality effect in these studies may have obscured the finding that CAPD produces superior peritoneal phosphate clearance than CCPD among lower transport groups with standard PD prescriptions. In our population, lower transporters were significantly more likely to be treated with CAPD and higher transporters more likely to be treated with CCPD. High transporters have more rapid equilibration of phosphate across the peritoneal membrane, which likely accounts for the lack of modality effect that we observed in this group. Thus, a propensity to treat higher transporters with CCPD and lower transporters with CAPD may mask the effect of modality when membrane status is not controlled for. The strengths of our study include a large study population and adjustment by multivariate linear regression analysis of the known variables that could influence peritoneal phosphate clearance. Moreover, we excluded all of the measurements of dialysis dose and phosphate clearance done in the first 3 mo of PD to remove the possible bias of incident patients with inadequate dialysis. We reported peritoneal phosphate clearance instead of peritoneal phosphate removal because it is assumed that phosphate removal is indicative merely of phosphate intake in the steady state and is not a measure of dialysis dose with respect to phosphate. One limitation is that this is a cross-sectional and observational study. We assessed a crosssection of the PD population who were receiving standard prescriptions and adequate dialysis on CAPD or APD, but did not attempt to assess the effect of tidal regimens, dwell times, or number of cycles on phosphate clearance. Conclusions This study contributes to our understanding of peritoneal phosphate clearance by highlighting the importance of peritoneal membrane transport status and PD modality. Peritoneal creatinine clearance, but not Kt/V urea, is a strong determinant of peritoneal phosphate clearance and may be used as a surrogate. In patients with inadequate phosphate control on APD, it is logical to consider PD prescription modifications to maximize dwell time and increase peritoneal creatinine clearance rather than an immediate increase in phosphate binder prescription. Acknowledgments We are grateful to the late Dr. Denis Pagé for his role in establishing the Ottawa Hospital Home Dialysis program and for his invaluable guidance in this and other academic endeavors. We gratefully acknowledge the substantial assistance by the PD nurses at the Home Dialysis unit of the Ottawa Hospital. Disclosures. None. References 1. Ansell D: Serum phosphate and outcomes in PD patients. Nephrol Dial Transplant 22: , Noordzij M, Korevaar JC, Bos WJ, Boeschoten EW, Dekker FW, Bossuyt PM, Krediet RT: Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 21: , Rufino M, de Bonis E, Martin M, Rebollo S, Martin B, Miguel R, Cobo M, Hernandez D, Torres A, Lorenzo V: Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13: 65 67, Sperschneider H, Gunther K, Marzoll I, Kirchner E, Stein G: Calcium carbonate (CaCO 3 ): An efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transplant 8: , Curtin RB, Svarstad BL, Keller TH: Hemodialysis patients noncompliance with oral medications. ANNA J 26: , Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK: Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: What are the implications? Am J Kidney Dis 43: , Zehnder C, Gutzwiller JP, Renggli K: Hemodiafiltration a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 52: , Nolph KD, Twardowski ZJ, Popovich RP, Rubin J: Equili-
7 Clin J Am Soc Nephrol 3: , 2008 Peritoneal Phosphate Clearance 1717 bration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med 93: , Sedlacek M, Dimaano F, Uribarri J: Relationship between phosphorus and creatinine clearance in peritoneal dialysis: Clinical implications. Am J Kidney Dis 36: , Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of [beta]2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70: , Gallar P, Ortega O, Gutierrez M, Munoz M, Hilara L, Oliet A, Rodriguez I, Gimenez E, Vigil A: Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options. [Spanish]. Nefrologia 20: , Twardowski Z, Nolph KO, Khanna R, Prowant BF, Ryan LP, Moore HL, Neilsen MP: Peritoneal equilibration test. Perit Dial Int 7: , Twardowski ZJ, Nolph KD, Khanna R, Gluck Z, Prowant BF, Ryan LP: Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. ASAIO Trans 32: , Venkataraman V, Nolph KD: Utilisation of PD modalities: Evolution. Semin Dial 15: , Mujais S, Story K: Peritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts. Kidney Int 70: S21 S26, Wilson J, Nissenson AR: Determinants in APD selection. Semin Dial 15: , Lo WK, Bargman JM, Burkart J, Krediet RT, Pollock C, Kawanishi H, Blake PG, ISPD Adequacy of Peritoneal Dialysis Working Group: Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 26: , National Kidney Foundation. Clinical practice recommendations for peritoneal dialysis adequacy. Am J Kidney Dis 48: S130 S158, Kim DJ, Do JH, Huh W, Kim YG, Oh HY: Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int 21: , Juergensen P, Eras J, McClure B, Kliger AS, Finkelstein FO: The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients. Int J Artif Organs 28: , Juergensen PH, Murphy AL, Kliger AS, Finkelstein FO: Increasing the dialysis volume and frequency in a fixed period of time in CPD patients: The effect on Kpt/V and creatinine clearance. Perit Dial Int 22: , 2002
Ana Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More information3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane
3/21/2017 Solute Clearance and Adequacy Targets in Peritoneal Dialysis Steven Guest MD Director, Medical Consulting Services Baxter Healthcare Corporation Deerfield, IL, USA Peritoneal Membrane Image courtesy
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationThe peritoneal equilibration test (PET) was developed THE SHORT PET IN PEDIATRICS. Bradley A. Warady and Janelle Jennings
Peritoneal Dialysis International, Vol. 27, pp. 441 445 Printed in Canada. All rights reserved. 0896-8608/07 $3.00 +.00 Copyright 2007 International Society for Peritoneal Dialysis THE SHORT PET IN PEDIATRICS
More informationPhosphate Clearance in Peritoneal Dialysis: Automated PD Compared with Continuous Ambulatory PD
Advances in Peritoneal Dialysis, Vol. 28, 2012 Dixie-Ann Sawin, Rainer Himmele, Jose A. Diaz Buxo Phosphate Clearance in Peritoneal Dialysis: Automated PD Compared with Continuous Ambulatory PD Although
More informationChapter 2 Peritoneal Equilibration Testing and Application
Chapter 2 Peritoneal Equilibration Testing and Application Francisco J. Cano Case Presentation FW, a recently diagnosed patient with CKD Stage 5, is a 6-year-old boy who has been recommended to initiate
More informationAdvances in Peritoneal Dialysis, Vol. 23, 2007
Advances in Peritoneal Dialysis, Vol. 23, 2007 Antonios H. Tzamaloukas, 1,2 Aideloje Onime, 1,2 Dominic S.C. Raj, 2 Glen H. Murata, 1 Dorothy J. VanderJagt, 3 Karen S. Servilla 1,2 Computation of the Dose
More informationTidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis
Kidney International, Vol. 57 (2000), 2603 2607 Tidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis PETER H. JUERGENSEN, A. LOLA MURPHY, KATHY A. PHERSON,
More informationAdequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial
http://www.kidney-international.org & 2006 International Society of Nephrology original article Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 22, 2006 Costas Fourtounas, Eirini Savidaki, Marilena Roumelioti, Periklis Dousdampanis, Andreas Hardalias, Pantelitsa Kalliakmani,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Mode of dialysis at initiation GUIDELINES
Date written: September 2004 Final submission: February 2005 Mode of dialysis at initiation GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationHyperphosphatemia is emerging as an independent
Chronic Kidney Disease Mineral Bone Disorder and Peritoneal Dialysis Peritoneal Dialysis International, Vol. 28 (2008), Supplement 2 Printed in Canada. All rights reserved. 0896-8608/08 $3.00 +.00 Copyright
More informationPeritoneal Dialysis Adequacy: Not Just Small- Solute Clearance
Advances in Peritoneal Dialysis, Vol. 24, 2008 Rajesh Yalavarthy, Isaac Teitelbaum Peritoneal Dialysis Adequacy: Not Just Small- Solute Clearance Two indices of small-solute clearance, Kt/V urea and creatinine
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE TABLE OF CONTENTS Introduction.... 3 SECTION 1: FUNDAMENTALS OF THE PRESCRIPTION.... 4 Getting Started: Patient Pathway to First Prescription.... 5 Volume
More informationYou can sleep while I dialyze
You can sleep while I dialyze Nocturnal Peritoneal Dialysis Dr. Suneet Singh Medical Director, PD, VGH Division of Nephrology University of British Columbia Acknowledgements Melissa Etheridge You can sleep
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE This quick reference guide will help serve as a reference tool for clinicians setting a patient s Peritoneal Dialysis (PD) prescription.
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES
Date written: August 2004 Final submission: July 2005 Monitoring patients on peritoneal dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More information02/21/2017. Assessment of the Peritoneal Membrane: Practice Workshop. Objectives. Review of Physiology. Marina Villano, MSN, RN, CNN
Assessment of the Peritoneal Membrane: Practice Workshop Marina Villano, MSN, RN, CNN marina.villano@fmc-na.com Objectives Briefly review normal peritoneal physiology including the three pore model. Compare
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationPERITONEAL DIALYSIS ADEQUACY: The KDOQI Guidelines and Beyond
PERITONEAL DIALYSIS ADEQUACY: The KDOQI Guidelines and Beyond John Burkart, M.D. Wake Forest University Baptist Medical Center CMO Health Systems Management 8/2014 John M. Burkart, MD Educational Grants
More informationPredictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran
Dialysis Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran Monir Sadat Hakemi, 1 Mehdi Golbabaei, 2 Amirahmad Nassiri, 3 Mandana
More informationSmart APD prescription. Prof. Wai Kei Lo Tung Wah Hospital The University of Hong Kong
Smart APD prescription Prof. Wai Kei Lo Tung Wah Hospital The University of Hong Kong Costing Comparison of Different Modes of RRT in Hong Kong in 2011 (Per Year) HK$300,000 HK$250,000 HK$200,000 HK$150,000
More informationContinuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis: What, Who, Why, and How? Review and Case Study
Advances in Peritoneal Dialysis, Vol. 33, 2017 Kunal Malhotra, Ramesh Khanna Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis: What, Who, Why, and How? Review and Case Study
More informationEarly Estimation of High Peritoneal Permeability Can Predict Poor Prognosis for Technique Survival in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hidetomo Nakamoto, 1,2 Hirokazu Imai, 2 Hideki Kawanishi, 2 Masahiko Nakamoto, 2 Jun Minakuchi, 2 Shinichi Kumon, 2 Syuichi Watanabe, 2 Yoshhiko Shiohira,
More informationad e quate adjective \ˈa-di-kwət\
PD Prescriptions and Adequacy Monitoring: The Basics Fundamentals of Dialysis in Children Seattle, Washington February 27th, 2016 Colin White Steve Alexander Brad Warady Alicia Neu Franz Schaefer Bruce
More informationSt George & Sutherland Hospitals PERITONEAL DIALYSIS UNIT RENAL DEPARTMENT Workplace Instruction (Renal_SGH_WPI_097)
PERITONEAL DIALYSIS (PD) PERITONEAL EQUILIBRATION TEST (PET) Cross references NSW Health PD2007_036 - Infection Control Policy SGH-TSH CLIN027 - Aseptic Technique - Competency and Education Requirements
More informationThe control of extracellular fluid volume (ECFV) is a
Comparison of Volume Overload with Cycler-Assisted versus Continuous Ambulatory Peritoneal Dialysis Sara N. Davison,* Gian S. Jhangri, Kailash Jindal,* and Neesh Pannu* *Division of Nephrology and Department
More informationAcid-base profile in patients on PD
Kidney International, Vol. 6, Supplement 88 (23), pp. S26 S36 Acid-base profile in patients on PD SALIM MUJAIS Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois Acid-base profile in patients
More informationIntermittent peritoneal dialysis (IPD) has occasionally
Peritoneal Dialysis International, Vol. 32, pp. 142 148 doi: 10.3747/pdi.2011.00027 0896-8608/12 $3.00 +.00 Copyright 2012 International Society for Peritoneal Dialysis INTERMITTENT PERITONEAL DIALYSIS:
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationPeritoneal Dialysis International, Vol. 16, pp /96$300+00
Peritoneal Dialysis International, Vol. 16, pp 302-306 0896-8608/96$300+00 Printed in Canada All rights reserved Copyright 1996 International Society for Peritoneal Dialysis CONTINUOUS PERITONEAL DIAL
More informationPD prescribing for all. QUESTION: Which approach? One size fits all or haute couture? (1) or (2)? The patient 18/03/2014.
PD prescribing for all Pr Max Dratwa Honorary consultant, Nephrology-Dialysis CHU Brugmann Université Libre de Bruxelles BSN 22 March 2014 QUESTION: Which approach? One size fits all or haute couture?
More informationDetermination of Peritoneal Transport Characteristics With 24-Hour Dialysate Collections: Dialysis Adequacy and Transport Test1
Determination of Peritoneal Transport Characteristics With 24-Hour Dialysate Collections: Dialysis Adequacy and Transport Test1 Michael V. Rocco,2 Jean R. Jordan, and John M. Burkart MV. Rocco, J.M. Burkart,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Peritoneal transport and ultrafiltration GUIDELINES
Date written: January 2004 Final submission: May 2004 Peritoneal transport and ultrafiltration GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe Physiology of Peritoneal Dialysis As Related To Drug Removal
The Physiology of Peritoneal Dialysis As Related To Drug Removal Thomas A. Golper, MD, FACP, FASN Vanderbilt University Medical Center Nashville, TN thomas.golper@vanderbilt.edu Clearance By Dialysis Clearance
More informationPERITONEAL EQUILIBRATION TEST. AR. Merrikhi. MD. Isfahan University of Medical Sciences
PERITONEAL EQUILIBRATION TEST AR. Merrikhi. MD. Isfahan University of Medical Sciences INTRODUCTION The peritoneal equilibration test (PET) is a semiquantitative assessment of peritoneal membrane transport
More informationPeritoneal Dialysis Prescriptions: A Primer for Nurses
Peritoneal Dialysis Prescriptions: A Primer for Nurses A Primer ABCs of PD R x Betty Kelman RN-EC MEd CNeph (C) Toronto General Hospital University Health Network Toronto, Ontario, Canada A moment to remember
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More informationSuperior dialytic clearance of b 2 -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis
original article http://www.kidney-international.org 26 International Society of Nephrology Superior dialytic clearance of b 2 -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationPredicting Clinical Outcomes in Peritoneal Dialysis Patients Using Small Solute Modeling
46 Annals of Clinical & Laboratory Science, vol. 35, no. 1, 2005 Predicting Clinical Outcomes in Peritoneal Dialysis Patients Using Small Solute Modeling Justin Westhuyzen, 1 Karen Mills, 2 and Helen Healy
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Optimising small solute clearances in peritoneal dialysis GUIDELINES
Optimising small solute clearances in peritoneal dialysis Date written: August 2004 Final submission: December 2004 GUIDELINES a. Aim to maintain residual renal function (RRF). Consider the use of ace
More informationVolume Management 2/25/2017. Disclosures statement: Objectives. To discuss evaluation of hypervolemia in peritoneal dialysis patients
Volume Management Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 14, 2017 Disclosures statement: Consultant: Allena, Becker Professional Education Grant
More informationChapter 12 PERITONEAL DIALYSIS
Chapter 12 PERITONEAL DIALYSIS B. Sunita A/P V. Bavanandan Anita Bhajan Manocha Lily Binti Mushahar Mohamad Zaimi Bin Abdul Wahab Sudhaharan Sivathasan PERITONEAL DIALYSIS 22nd Report of the SECTION 12.1:
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationDialysis therapy remains the mainstay in the treatment
Proceedings of the ISPD 2006 The 11th Congress of the ISPD 0896-8608/07 $3.00 +.00 August 25 29, 2006, Hong Kong Copyright 2007 International Society for Peritoneal Dialysis Peritoneal Dialysis International,
More informationEffect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study
Kidney International, Vol. 64 (2003), pp. 649 656 DIALYSIS TRANSPLANTATION Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study WAI-KEI LO, YIU-WING HO, CHUN-SANG
More informationMaintaining Peritoneal Dialysis Adequacy: The Process of Incremental Prescription
Advances in Peritoneal Dialysis, Vol. 34, 2018 Susie Q. Lew Maintaining Peritoneal Dialysis Adequacy: The Process of Incremental Prescription Urea kinetics (weekly Kt/V) greater than 1.7 generally define
More informationEffect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations
NDT Advance Access published November 9, 2005 Nephrol Dial Transplant (2005) 1 of 8 doi:10.1093/ndt/gfi248 Original Article Effect of previously failed kidney transplantation on peritoneal dialysis outcomes
More information2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home
Fluid Management 2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home Objectives Define euvolemia Determine factors which contribute to fluid imbalance Discuss strategies
More informationThe greatest benefit of peritoneal dialysis (PD) is the
Peritoneal Dialysis International, Vol. 26, pp. 150 154 Printed in Canada. All rights reserved. 0896-8608/06 $3.00 +.00 Copyright 2006 International Society for Peritoneal Dialysis COMBINATION THERAPY
More informationBrief communication (Original)
Asian Biomedicine Vol. 8 No. 1 February 2014; 67-73 DOI: 10.5372/1905-7415.0801.263 Brief communication (Original) Long-term clinical effects of treatment by daytime ambulatory peritoneal dialysis with
More informationPRESERVATION OF RESIDUAL RENAL FUNCTION IN DIALYSIS PATIENTS: EFFECTS OF DIALYSIS-TECHNIQUE RELATED FACTORS
Peritoneal Dialysis International, Vol. 21, pp. 52 57 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2001 International Society for Peritoneal Dialysis PRESERVATION OF RESIDUAL
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Level of renal function at which to initiate dialysis GUIDELINES
Level of renal function at which to initiate dialysis Date written: September 2004 Final submission: February 2005 GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR
More informationPeritoneal dialysis adequacy: A model to assess feasibility with various modalities
Kidney International, Vol. 55 (1999), pp. 2493 2501 Peritoneal dialysis adequacy: A model to assess feasibility with various modalities JOSE A. DIAZ-BUXO, FRANK A. GOTCH, TOM I. FOLDEN, SHELDEN ROSENBLUM,
More informationThe definition of peritoneal dialysis (PD) adequacy has
Peritoneal Dialysis International, Vol. 29, pp. 465 471 Printed in Canada. All rights reserved. 0896-8608/09 $3.00 +.00 Copyright 2009 International Society for Peritoneal Dialysis DIALYTIC PHOSPHATE REMOVAL:
More informationHome Dialysis. Peritoneal Dialysis. Home Hemodialysis
Home Dialysis The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any and
More informationUrgent start PD: Putting the person first
Urgent start PD: Putting the person first Arsh Jain MD, FRCPC, MSc ADC 2019 Who can we target with urgent start PD? Late or not referred Early referral Urgent dialysis start HD catheter Facility HD Who
More informationPresternal Catheter Design An Opportunity to Capitalize on Catheter Immobilization
Advances in Peritoneal Dialysis, Vol. 26, 2010 Dale G. Zimmerman Presternal Catheter Design An Opportunity to Capitalize on Catheter Immobilization Effective immobilization of the peritoneal catheter has
More informationOriginal Article. Key words: Icodextrin, peritoneal dialysis, metabolic effects, ultrafiltration
Original Article 133 Clinical Experience of One-Year Icodextrin Treatment in Peritoneal Dialysis Patients Chun-Shuo Hsu *, Chien-Yu Su **, Chih-Hung Chang ***, Kao-Tai Hsu **, King-Kwan Lam **, Shang-Chih
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (994) 9: 399-403 Original Article Nephrology Dialysis Transplantation Nocturnal intermittent peritoneal dialysis G. Woodrow, J. H. Turney, J. A. Cook, J. Gibson, S. Fletcher, A.
More informationProceedings of the ISPD 2006 The 11th Congress of the ISPD /07 $ MAXIMIZING THE SUCCESS OF PERITONEAL DIALYSIS IN HIGH TRANSPORTERS
Proceedings of the ISPD 2006 The 11th Congress of the ISPD 0896-8608/07 $3.00 +.00 August 25 29, 2006, Hong Kong Copyright 2007 International Society for Peritoneal Dialysis Peritoneal Dialysis International,
More informationOverweight Rather Than Malnutrition Is Widely Prevalent in Peritoneal Dialysis Patients
Advances in Peritoneal Dialysis, Vol. 25, 2009 Ana P. Bernardo, 1 Isabel Fonseca, 2 Anabela Rodrigues, 2 Maria J. Carvalho, 2 António Cabrita 2 Overweight Rather Than Malnutrition Is Widely Prevalent in
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationPhosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients
Nephrol Dial Transplant (2016) 31: 1508 1514 doi: 10.1093/ndt/gfv414 Advance Access publication 31 January 2016 Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients Pieter Evenepoel
More informationFistula First? Vascular Symposium 4/28/18
Fistula First? Vascular Symposium 4/28/18 Disclosure I have no financial interest to disclose connected to any of the information presented in this discussion Objectives Scope of Problem Benefits of PD
More informationKieran McCafferty 1,2, Stanley Fan 1 and Andrew Davenport 2. clinical investigation. see commentary on page 15
http://www.kidney-international.org & 2013 International Society of Nephrology see commentary on page 15 Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve
More informationOriginal Article ABSTRACT
Original Article Peritoneal Equilibration Test (PET) Analysis among Filipino Children on Chronic Peritoneal Dialysis at the National Kidney and Transplant Institute: A Cross-Sectional Study Elmer Kent
More informationWhat is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test
1 2 3 What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test 4 Background information about the PET 1983 Dr. Twardowski and colleagues began measuring
More informationPatient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study
http://www.kidney-international.org & 2006 International Society of Nephrology Patient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study S Mujais
More informationNephrology. Renal Replacement in End-Stage Renal Disease Patients over 75 Years Old. ABC Fax
American Journal of Nephrology Original Article: Basic Sciences Am J Nephrol 2003;23:7 77 DOI: 0.59/000068040 Received: July 23, 2002 Accepted: October 2, 2002 Renal Replacement in End-Stage Renal Disease
More informationIntravenous Iron Does Not Affect the Rate of Decline of Residual Renal Function in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hemal Shah, Ashutosh Shukla, Abirami Krishnan, Theodore Pliakogiannis, Mufazzal Ahmad, Joanne M. Bargman, Dimitrios G. Oreopoulos Intravenous Iron Does Not
More informationChanges in the Peritoneal Equilibration Test in Selected Chronic Peritoneal Dialysis Patients1
hanges in the Peritoneal Equilibration Test in Selected hronic Peritoneal Dialysis Patients1 Wai-Kei Lo, Alessandra Brendolan, Barbara F. Prowant, Harold L. Moore, Ramesh Khanna, Zbylut J. Twardowski,
More informationGlucose sparing in peritoneal dialysis: Implications and metrics
http://www.kidney-international.org & 26 International Society of Nephrology Glucose sparing in peritoneal dialysis: Implications and metrics C Holmes 1 and S Mujais 1 1 Renal Division, Baxter Healthcare
More informationPredictive Factors for Withdrawal from Peritoneal Dialysis: A Retrospective Cohort Study at Two Centers in Japan
Advances in Peritoneal Dialysis, Vol. 33, 2017 Yasuhiro Taki, 1 Tsutomu Sakurada, 2 Kenichiro Koitabashi, 2 Naohiko Imai, 1 Yugo Shibagaki 2 Predictive Factors for Withdrawal from Peritoneal Dialysis:
More informationChanges in Patient and Technique Survival over Time among Incident Peritoneal Dialysis Patients in Canada
Article Changes in Patient and Technique Survival over Time among Incident Peritoneal Dialysis Patients in Canada Jeffrey Perl,* Ron Wald,* Joanne M. Bargman, Yingbo Na, S. Vanita Jassal, Arsh K. Jain,
More informationDe Novo Hypokalemia in Incident Peritoneal Dialysis
Original investigation 73 1) De Novo Hypokalemia in Incident Peritoneal Dialysis Patients: A 1-Year Observational Study Ji Yong Jung, M.D., Jae Hyun Chang, M.D., Hyun Hee Lee, M.D., Wookyung Chung, M.D.
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationAutomated peritoneal dialysis (APD) has, in recent
VIIth International Course on Peritoneal Dialysis May 23 26, 2000, Vicenza, Italy Peritoneal Dialysis International, Vol. 20, Suppl. 2 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal
More informationCHAPTER 12. Peritoneal Dialysis
23rd Report of the PERITONEAL DIALYSIS CHAPTER 12 Peritoneal Dialysis Sunita Bavanandan Anita Bhajan Manocha Lily Mushahar Mohamad Zaimi Bin Abdul Wahab PERITONEAL DIALYSIS 23rd Report of the SECTION 12.1:
More informationMethods. Original Article. Abstract
Original Article Influence of Peritoneal Transport Characteristics on Nutritional Status and Clinical Outcome in Chinese Diabetic Nephropathy Patients on Peritoneal Dialysis Ji Chao Guan 1,2, Wei Bian
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationPhysiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT
Physiology of Blood Purification: Dialysis & Apheresis Jordan M. Symons, MD University of Washington School of Medicine Seattle Children s Hospital Outline Physical principles of mass transfer Hemodialysis
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationGambrosol Trio, clinical studies 91 Glitazone, malnutrition-inflammationatherosclerosis
Subject Index Acidosis, see Metabolic acidosis Activated carbon, sorbents 337 Adipokines adipose tissue and systemic inflammation 169 functions 167 169 prospects for study in renal patients 171 Adiponectin,
More informationDaily peritoneal ultrafiltration predicts patient and technique survival in anuric peritoneal dialysis patients
2322 X. Lin et al. gy data. Journal of the American Statistical Association 1993; 88: 400 409 32. Bodnar E, Blackstone EH. An actual problem: another issue of apples and oranges. J Thorac Cardiovasc Surg
More informationPeritoneal Dialysis International, Vol. 16, pp /96$ AUTOMATED PERITONEAL DIALYSIS
Peritoneal Dialysis International, Vol. 16, pp 307-315 0896-8608/96$300+00 Printed in Canada All rights reserved Copyright 1996 International Society for Peritoneal Dialysis RAPID DECLINE OF RESIDUAL RENAL
More informationThe Intact Nephron Hypothesis in Reverse: An Argument In Favor of Incremental Initiation Of Dialysis (With Residual Kidney Function)
The Intact Nephron Hypothesis in Reverse: An Argument In Favor of Incremental Initiation Of Dialysis (With Residual Kidney Function) Thomas A. Golper MD, FACP, FASN Vanderbilt University Medical Center
More informationTalking with Patients About Home Therapies
Talking with Patients About Home Therapies Sherri L. Bresn BS, BSN, RN, CNN 1 This presentation is not intended to replace the medical diagnosis, and/or prescription for therapy as determined by a practicing
More informationWhy NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels. Page 1
Why NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels Page 1 Are you prepared? 4.1% Annual increase 1 in European dialysis patients Reference: 1. 2017 USRDS Annual Data Report Reference
More informationMETABOLISM AND NUTRITION WITH PD OBESITY. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
METABOLISM AND NUTRITION WITH PD OBESITY Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 Body Size in Patients New to Dialysis United States Body Mass Index, kg/m2 33 31
More informationIncremental Hemodialysis
The 25 th Budapest Nephrology School, 2018 Incremental Hemodialysis a story about Hemodialysis and the Residual Kidney Function - a fairy tale? Csaba Ambrus Szent Imre Teaching Hospital, Div. of Nephrology-Hypertension
More informationConcern about the decreasing use of peritoneal dialysis
Page 1 of 8 Peritoneal Dialysis International Peritoneal Dialysis International, Vol. 30, pp. doi: 10.3747/pdi.2008.00277 0896-8608/10 $3.00 +.00 Copyright 2010 International Society for Peritoneal Dialysis
More informationI. CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY
I. CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY GUIDELINE 1. INITIATION OF DIALYSIS 1.1 Preparation for kidney failure: Patients who reach chronic kidney disease (CKD) stage 4 (estimated
More informationEvaluation and management of nutrition in children
Evaluation and management of nutrition in children Date written: May 2004 Final submission: January 2005 Author: Elisabeth Hodson GUIDELINES No recommendations possible based on Level I or II evidence
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationUW MEDICINE PATIENT EDUCATION. Peritoneal Dialysis. A treatment option for kidney disease. There are 2 types of PD: continuous ambulatory
UW MEDICINE PATIENT EDUCATION Peritoneal Dialysis A treatment option for kidney disease Class Goals 1. Understand the purpose and basic principles of continuous ambulatory peritoneal dialysis (CAPD). 2.
More informationFailure to obtain adequate rates of ultrafiltration (UF) is
Page 1 of 6 Peritoneal Dialysis International Peritoneal Dialysis International, inpress www.pdiconnect.com 0896-8608/16 $3.00 +.00 Copyright 2016 International Society for Peritoneal Dialysis ANALYSIS
More information